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Background: In Ethiopia, there is a growing concern about the increasing rates of loss to follow-up (LTFU) in HIV
programs among people waiting to start HIV treatment. Unlike other African countries, there is little information
about the factors associated with LTFU among pre-antiretroviral treatment (pre-ART) patients in Ethiopia. We
conducted a case–control study to investigate factors associated with pre-ART LTFU in Ethiopia.
Methods: Charts of HIV patients newly enrolled in HIV care at Gondar University Hospital (GUH) between
September 11, 2008 and May 8, 2011 were reviewed. Patients who were “loss to follow-up” during the pre-ART
period were considered to be cases and patients who were “in care” during the pre-ART period were controls.
Logistic regression analysis was used to explore factors associated with pre-ART LTFU.
Results: In multivariable analyses, the following factors were found to be independently associated with pre-ART
LTFU: male gender [Adjusted Odds Ratio (AOR) = 2.00 (95% CI: 1.15, 3.46)], higher baseline CD4 cell count (251–300
cells/μl [AOR = 2.64 (95% CI: 1.05, 6.65)], 301–350 cells/μl [AOR = 5.21 (95% CI: 1.94, 13.99)], and >350 cells/μl
[AOR = 12.10 (95% CI: 6.33, 23.12)] compared to CD4 cell count of ≤200 cells/μl) and less advanced disease stage
(WHO stage I [AOR = 2.81 (95% CI: 1.15, 6.91)] compared to WHO stage IV). Married patients [AOR = 0.39
(95% CI: 0.19, 0.79)] had reduced odds of being LTFU. In addition, patients whose next visit date was not
documented on their medical chart [AOR = 241.39 (95% CI: 119.90, 485.97)] were more likely to be LTFU.
Conclusion: Our study identified various factors associated with pre-ART LTFU. The findings highlight the
importance of giving considerable attention to pre-ART patients’ care from the time that they learn of their
positive HIV serostatus. The completeness of the medical records, the standard of record keeping and
obstacles to retrieving charts also indicate a serious problem that needs due attention from clinicians and
data personnel.
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Sub-Saharan Africa bears the lion’s share of the global
Human Immunodeficiency Virus (HIV) burden, with
22.5 million infected people, which constitutes 68% of
the global total [1]. According to the Ethiopian HIV re-
lated estimates and projections for the year 2012, there
are759268 People Living with HIV/AIDS (PLHIV) in
Ethiopia which is 1.3% of the national adult HIV* Correspondence: ismaelahmed2003@gmail.com
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reproduction in any medium, provided the orprevalence. The Amhara region, which is one of the nine
regional states of Ethiopia located in the northern part
of the country, carries 27% of the national HIV burden
with an estimated 1.4% adult HIV prevalence [2].
Ethiopia introduced a fee based Anti-Retroviral Treat-
ment (ART) program in 2003. Since 2005, much pro-
gress has been made in making free ART available to a
large number of Ethiopians [3]. By the end of June 2011,
out of 580909 PLHIV who had been enrolled in chronic
care, 333434 (57%) patients had started ART but only
247805 (74%) were currently on treatment [4].Ltd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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LTFU in HIV programs among people already on treat-
ment and those waiting to start HIV treatment. Studies
from Ethiopia, South Africa, Uganda, and Cambodia have
demonstrated that there is a high rate of pre-ART mortal-
ity and LTFU [5-9]. However, compared to patients who
have started ART, less emphasis has been given to the
follow-up of pre-ART patients, making them a neglected
population [5,10,11]. Unlike the follow-up of PLHIV who
are taking ART, there is no standardized definition of
LTFU and appointment system for pre-ART patients and
this contributes to the challenges of tracing those LTFU in
Ethiopia [5]. This gap highlights the need for greater focus
upon retention of pre-ART patients from the beginning of
HIV care, not just after patients have been initiated on
ART. In Ethiopia, there is little information about the
magnitude of the problem or the associated factors that
contribute to LTFU among pre-ART patients. Therefore,
this study set out to identify factors associated with pre-
ART LTFU among newly enrolled HIV-infected patients.
Methods
Study design
The study design was a case–control study using chart re-
view of HIV patients newly enrolled in pre-ART care retro-
spectively between September 11, 2008 and May 8, 2011.
Study setting
The study was conducted in Gondar University Hospital,
Gondar town in the Amhara region of Ethiopia, about 735
kilometers north of the capital city Addis Ababa. The hos-
pital has 400 beds and serves more than five million
people. The hospital began ART service provision in
March 2005. In August 2007, the hospital started HIV/
AIDS case management program by deploying trained ad-
herence case managers and adherence supporters to assess
patients’ needs, develop patient-centered care plan, and
provide adherence counseling, health education, psycho-
social support, trace patients who are LTFU, monitor
patients “at-risk for non-adherence” and link patients to
community resources [12]. According to the Ethiopian
guideline for the implementation of HIV/AIDS case
management, adherence case managers are trained non-
health care professionals who are high school graduate
with some experience on HIV/AIDS. Adherence sup-
porters are PLHIV with a minimum of an 8th grade educa-
tion that are enrolled in HIV care and demonstrated good
adherence to HIV care. The guideline sets clinical and so-
cial criteria including poor adherence, history of other
chronic illnesses, history of substance abuse, problems of
accessing food, lack of shelter, lack of psychosocial sup-
port, etc. to screen and identify “at-risk for non-adherence”
patients or patients who may likely not adhere to treatment
and care and potentially become LTFU [3].Patients are linked to the HIV clinic either from HIV
testing clinics within the hospital or formally referred
(transferred in) by other health facilities. At presenta-
tion to the clinics, all patients undergo a complete
assessment using standardized intake forms whereby
a full clinical history and examination is conducted to
determine WHO HIV disease staging and screen for the
presence of opportunistic diseases. According to the
national guideline, HIV-positive adults and adolescents
are considered eligible for ART if they are in WHO
clinical stage IV (irrespective of CD4 count), or in stage
III if the CD4 cell count is ≤350 cells/μl, or in any
of the WHO clinical stages if the CD4 cell count is <200
cells/μl. ART is also recommended for all patients
with active pulmonary tuberculosis (TB) with CD4 cell
count <350 cells/μl, or patients with extra-pulmonary
or disseminated TB irrespective of their CD4 cell count.
If CD4 cell count measurement is not available, all
patients with active TB are eligible for ART. Non-
eligible patients are provided with an appointment to
attend the hospital every three months for cotrimo-
xazole preventive therapy (CPT) and every six months
for laboratory evaluation (including measurement of
CD4 cell count) [13].
In GUH, patients who are eligible for ART receive
preliminary counseling and then are asked to return
home with a cotrimoxazole prescription (if applicable)
and prepare for ART initiation within two weeks. They
are requested to come back to the hospital accompanied
by a relative, if possible, to foster a supportive home
environment and reinforce the importance of treatment
adherence. All new HIV positive patients who are
enrolled into chronic HIV care are linked to adherence
case managers for counseling and education on HIV
infection and the importance of adherence to care. The
adherence case managers also conduct a needs ass-
essment to identify patients who are “at-risk for non-
adherence” [3]. There is a tracking system in place to
trace patients who are LTFU during the pre-ART and
ART periods. However, unlike ART patients who are
labeled as “lost” when patients have not seen for more
than one month and “dropped” when having been loss
to follow-up for over three months, there is no
standardized definition of LTFU being used for pre-
ART patients. This makes it a challenge to track
pre-ART patients and identify LTFU in a timely fashion
[5]. By the end of June 2011, a total of 9236 HIV pa-
tients had been enrolled in HIV chronic care service
and 6178 had been initiated on ART. At the time of the
study, the ART clinic was equipped with a total of 27
trained staff, including one physician, one health officer,
eight nurses, two pharmacy technicians, three adher-
ence case managers, eight adherence supporters, and
four data personnel.
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The study population was those HIV positive patients
who were newly enrolled and followed up in the pre-
ART care at GUH from September 11, 2008 to May 8,
2011. HIV patients who were aged <15 years old, preg-
nant, transferred in from another health facility, trans-
ferred out to another health facility and known to have
died before starting ART were excluded from the study.
In addition to this, those patients who started ART
within the first two weeks following pre-ART enrollment
were excluded from the study due to the short pre-ART
follow-up period.
Variables
In this study, the explanatory variables were socio-
demographic and clinical variables including age, gender,
marital status, level of education, religion, residence, pa-
tient referral information, employment status, HIV dis-
closure status, history of TB, baseline CD4 count, and
WHO staging and the dependent variable was pre-ART
LTFU. The major pre-ART outcome was defined and
analyzed as ‘pre-ART loss to follow-up’ or ‘in care’.
Definitions
We defined ‘Pre-ART loss to follow-up’ (cases) to in-
clude patients who were not on ART and did not return
for care for a period of one month or more since their
most recent documented appointment date, [5,14,15].
For patients whose next appointment date was not doc-
umented, ‘pre-ART loss to follow-up’ included patients
who were not on ART and did not return to care for
seven months or more since their last hospital visit.
Patients who were ‘in care’ (controls) were defined as
patients who were alive, followed pre-ART care as
scheduled [16], visited the hospital within seven months
of their last visit, or were currently on ART.
Measurement
The data sources were the Federal Ministry of Health
patients’ registration database and intake forms which
are completed during the enrollment of HIV patients in
chronic care. The data abstraction tool for chart review
was prepared based on the information contained within
the patient registration and follow-up card, including the
socio-demographic and clinical variables of interest.
Once eligible patients for the study were identified based
on the inclusion criteria, study data was abstracted by
four experienced ART prescriber nurses.
Patients’ length of follow-up time in pre-ART care was
grouped in to less than one month, one to six months,
seven to 12 months and greaterthan12 months for ana-
lysis. Accordingly, LTFU patients who only had the first
visit to HIV clinic were categorized under less than one
month follow-up time in pre-ART care.Study size
The sample size was calculated using the following as-
sumptions for an unmatched case–control study design:
95% confidence interval (CI), 80% power, 25% level of ex-
posure in the ‘in care’ (control) group, 1:2 ratio of cases-
to-controls, and 1.5 expected odds ratio. According to the
data from GUH HIV clinic, about 3000 PLHIV were en-
rolled in pre-ART care in the period of September 11,
2008 to May 8, 2011, amounting to 32 months of cohort
data to be studied. After identifying the list of all eligible
study subjects, cases and controls were listed separately
and simple random sampling technique was used to select
the sample cases and controls using SPSS version 18.
Data analysis
Data coding, entry and cleaning was carried out using
Epi Info version 3.5.1 and the analysis was carried
out using SPSS version 18. Univariate analysis was
carried out to describe baseline socio-demographic
and clinical characteristics of the study subjects using
simple frequency distribution. Chi-squared tests were
used to measure the significance of differences in
socio-demographic and clinical characteristic between
cases and controls. Confounders were controlled for
during the analysis stage using logistic regression and
computed adjusted odds ratios with 95% confidence
intervals. We have also checked for interaction be-
tween variables using the logistic regression after cre-
ating the interaction terms.
Charts with incomplete data were entered as “missing”
and the rate of missing data for different variables was
below 5% except the employment status variable which
was excluded without replacement from the logistic re-
gression analysis.
Ethical approval
Ethical clearance was obtained from the institutional
review board of the University of Gondar and Addis
Continental Institute of Public Health. Confidentiality of
patients’ data was ensured. While reviewing patients’ re-
cords, non-personal identifiers such as patients’ medical
registration number and pre-ART number were used to
distinguish study subjects during data collection. We
communicated the list of LTFU patients to adherence
supporters for future tracing to establish their current
status and assist them to resume their care.
Results
Between September 11, 2008 and May 8, 2011, a total of
3035 (1240 males and 1795 females) HIV patients were
newly enrolled for HIV care at GUH ART clinic. Of
these, 1979 were eligible for this study based on the in-
clusion criteria. Of the eligible patients, 8% (n=162) of
pre-ART patients were excluded from the study because
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1817 study population, 70.8% (n=1287) were patients
who were under active follow-up for their HIV care
while the other 29.2% (n=530) were lost to follow-up
during the pre-ART period (Figure 1). In this study, a
total of 1089 (363 cases and 726 controls) patient charts
were reviewed from 1817 study population.
Baseline socio-demographic characteristics
of the study population
Out of the 1089 study subjects analyzed, 59.7% (650)
were female. The majority (59.5%; n=316) of patients
who were pre-ART LTFU were also females. By the time
of enrollment into HIV care, nearly half (45.7%; n=498)
of the study subjects were between 25–34 years of age.
The mean age distribution was 32.7 years with a stand-
ard deviation of 9.12. Of the total study population,
45.7% (n=498) were married. With regards to educa-
tional status of study subjects, 38.3% (n=417) of patients
completed secondary school or above followed by 35.3%
(n=384) of patients with no education. The majority








Figure 1 Profiles of HIV clients at GUH (September 11, 2008 to May 8orthodox Christianity. Just over one quarter (26.9%;
n=293) of the study subjects enrolled in HIV care lived
outside the city of Gondar (Table 1).
When we compared cases with controls, the age distribu-
tion (p≤0.001), marital status (p=0.013) and educational sta-
tus (p=0.010) were significantly different in cases and
controls. A higher proportion of LTFU individuals (22.9%)
were younger (age 15–24) when compared to those who
were in care (12.8%). Higher proportions of LTFU individ-
uals had never been married (21.2%) or were divorced or
separated (32.2%) compared to those who were in care
(15.6% and 27.8%, respectively). Moreover, a higher propor-
tion of LTFU individuals had less education (no education,
38.6%; primary level education, 29.5%) compared to those
who were in care (33.6% and 24.9%, respectively) (Table 1).
Baseline clinical characteristics and chronic
care follow-up status
Among the 1076 patients who had their baseline CD4
cell count documented, 56.8% (n=611) had CD4 count
≤200 cell/μl and 20.0% (n=215) had a CD4 count >350
cell/μl. In contrast, among the 1070 charts that hadPre-ART LTFU 
n=530 (29.2%) 
Lost charts (n=162, 8.2%) 
Ineligible: n=1056 
Started ART within 2 weeks  355 
Age <15 Years  289 
Transferred-in  314 
Transferred-out 64 
Pregnant  28 
Dead   6 
, 2011).
Table 1 Baseline socio-demographic characteristics of pre-ART patients at GUH (September 11, 2008 to May 8, 2011)
Variables Total, n (%) In care, n (%) LTFU, n (%) P-value
Gender (N=1089) 0.930
Male 439 (40.3) 292 (40.2) 147 (40.5)
Female 650 (59.7) 434 (59.8) 216 (59.5)
Age group (N=1089) <0.001
15-24 176 (16.2) 93 (12.8) 83 (22.9)
25-34 498 (45.7) 327 (45.0) 171 (47.1)
35-44 283 (26.0) 207 (28.5) 76 (20.9)
44+ 132 (12.1) 99 (13.6) 33 (9.1)
Marital status (N=1089) 0.013
Never married 190 (17.4) 113 (15.6) 77 (21.2)
Married 498 (45.7) 351 (48.3) 147 (40.5)
Divorced/separated 319 (29.3) 202 (27.8) 117 (32.2)
Widow/er 82 (7.5) 60 (8.3) 22 (6.1)
Educational status (N=1089) 0.010
No education 384 (35.3) 244 (33.6) 140 (38.6)
Primary 288 (26.4) 181 (24.9) 107 (29.5)
Secondary & above 417 (38.3) 301 (41.5) 116 (32.0)
Religion (N=1089) 0.131
Muslim 87 (8.0) 55 (7.6) 32 (8.8)
Orthodox 991 (91.0) 661 (91.0) 330 (90.9)
Others 11 (1.0) 10 (1.4) 1 (.3)
Place of residence (N=1089) 0.411
Gondar 796 (73.1) 525 (72.3) 271 (74.7)
Out of Gondar 293 (26.9) 201 (27.7) 92 (25.3)
Employment status (N= 995) 0.186
Employed 568 (57.1) 382 (58.6) 186 (54.2)
Unemployed 427 (42.9) 270 (41.4) 157 (45.8)
Availability of emergency contact person (N=1089) 0.396
Yes 955 (87.7) 641 (88.3) 314 (86.5)
No 134 (12.3) 85 (11.7) 49 (13.5)
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(41.7%; n=446) of patients were stage III followed by
24% (n=257) stage I patients. Among 1044 patient charts
that had documentation on past history of tuberculosis,
21.3% (n=222) patients had a history of tuberculosis
treatment.
The distribution of CD4 cell count categories, WHO
stage and recorded next appointment date were signifi-
cantly different in cases versus controls (p≤0.001). A higher
proportion of LTFU patients (42.2%) had a CD4 count
>350 cell/μl when compared to those who were in care
(9.1%). Similarly, higher proportions of LTFU patients
(34%) were in WHO stage I compared to those who were
in care (19.1%). Individuals who were in care (97.8%) were
more likely to have their next appointment date recorded
than those that were LTFU (20.4%) (Table 2).Concerning the length of follow-up time in HIV
chronic care, most (61.7%; n=672) of the patients had
less than one month follow-up during their pre-ART
period. The median length of time in the pre-ART
period was less than one month, ranging from less than
one up to 37 months. Out of a total of 363 pre-ART
LTFU cases, 86% (n=312) had less than one month of
follow-up, 10.4% (n=38) had between one and six
months of follow-up, and 3.6% (n=13) had more than
seven months of follow-up time in the clinic. When we
examine the time of LTFU of the 363 pre-ART LTFU
patients, 84.8% (n=308) of LTFU patients failed to return
since their first clinic visit or did not show up after the
date of enrollment.
Regarding the practice of clinicians on documenting the
next appointment date of patients in pre-ART care, the
Table 2 Baseline clinical characteristics of pre-ART patients at GUH (September 11, 2008 to May 8, 2011)
Variables Total, n (%) In care, n (%) LTFU, n (%) P-value
Patient referral information (N= 1081) 0.118
Within the hospital 796 (73.6) 518 (72.1) 278 (76.6)
Outside the hospital 285 (26.4) 200 (27.9) 85 (23.4)
Disclosure of HIV+ status (N=1089) 0.174
To spouse/family members only 616 (56.6) 423 (58.3) 193 (53.2)
To relatives/friends only 86 (7.9) 61 (8.4) 25 (6.9)
To spouse/family members & relatives/friends 35 (3.2) 23 (3.2) 12 (3.3)
To no one 352 (32.3) 219 (30.2) 133 (36.6)
CD4 cell count/μl (N= 1076) <0.001
≤ 200 611 (56.8) 505 (69.8) 106 (30.0)
201-250 111 (10.3) 73 (10.1) 38 (10.8)
251-300 75 (7.0) 50 (6.9) 25 (7.1)
301-350 64 (5.9) 29 (4.0) 35 (9.9)
> 350 215 (20.0) 66 (9.1) 149 (42.2)
WHO stage (N= 1070) <0.001
Stage I 257 (24.0) 137 (19.1) 120 (34.0)
Stage II 194 (18.1) 126 (17.6) 68 (19.3)
Stage III 446 (41.7) 332 (46.3) 114 (32.3)
Stage IV 173 (16.2) 122 (17.0) 51 (14.4)
History of TB treatment (N= 1044) 0.058
Yes 222 (21.3) 159 (23.0) 63 (17.9)
No 822 (78.7) 533 (77.0) 289 (82.1)
Next appointment recorded (N= 1089) <0.001
Yes 784 (72.0) 710 (97.8) 74 (20.4)
No 305 (28.0) 16 (2.2) 289 (79.6)
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medical record for more than a quarter (28%; n=305) of
patients (Table 2).
Socio-demographic and clinical factors associated with
pre-ART LTFU
After controlling for the effects of gender, age, marital
status, educational status, place of residence, HIV dis-
closure, history of tuberculosis treatment, CD4 cell
count, WHO stage, and record of next appointment, five
variables were found to be associated significantly with
pre-ART LTFU. As shown in Table 3, males had twice
the odds of being LTFU during the pre-ART period
compared to females (adjusted OR = 2.00 (95% CI: 1.15,
3.46)). Married patients had a 61% reduced odds of be-
ing LTFU during the pre-ART period compared to those
who had never been married (adjusted OR = 0.39 (95%
CI: 0.19, 0.79)). Compared to patients with a baseline
CD4 count ≤200 cells/μl, the adjusted odds ratio for be-
ing LTFU before starting ART was 2.64 (95% CI: 1.05,
6.65), 5.21 (95% CI: 1.94, 13.99), and 12.10 (95% CI:6.33, 23.12) for patients with a CD4 count of 251–300
cells/μl, 301–350 cells/μl, and >350 cells/μl respectively.
Similarly, patients who were in WHO stage I at baseline,
had an adjusted odds ratio for LTFU during the pre-
ART period of 2.81 (95% CI: 1.15, 6.91) when compared
to patients who were in WHO stage IV.
Patients whose next appointment date was not docu-
mented on their chart had substantially increased odds of
being LTFU during the pre-ART period compared to
those who had a record of the next appointment date doc-
umented (adjusted OR = 241.39 (95% CI: 119.90, 485.97).
Discussion
This study is one of the few reports from a resource
limited-setting to describe the factors associated with
LTFU among a pre-ART population of PLHIV. This group
of patients has not been well studied compared to PLHIV
who are receiving ART. This is despite emerging evidence
of the poor disease outcomes in this pre-ART group. This
highlights the need for greater focus upon retention of
pre-ART patients from the beginning of HIV care, and not
Table 3 Socio-demographic and clinical factors associated with pre-ART loss to follow-up at GUH
Crude OR (95% CI) Adjusted+ OR (95% CI)
Variables n total n (%) OR 95% CI OR 95% CI
Gender 1089
Male 439 (40.3) 1.01 (0.78, 1.31) 2.00 (1.15, 3.46)*
Female 650 (59.7) 1.00 1.00
Age group 1089
15-24 176 (16.2) 1.00 1.00
25-34 498 (45.7) 0.59 (0.41, 0.83)* 0.80 (0.40, 1.61)
35-44 283 (26.0) 0.41 (0.28, 0.61)* 0.63 (0.28, 1.41)
44+ 132 (12.1) 0.37 (0.23, 0.61)* 0.77 (0.30, 2.00)
Marital status 1089
Never married 190 (17.4) 1.00 1.00
Married 498 (45.7) 0.62 (0.43, 0.87)* 0.39 (0.19, 0.79)*
Divorced/separated 319 (29.3) 0.85 (0.59, 1.23) 1.18 (0.57, 2.44)
Widow/er 82 (7.5) 0.54 (0.31, 0.95)* 0.54 (0.18 , 1.68)
Educational status 1089
No education 384 (35.3) 1.00 1.00
Primary 288 (26.4) 1.03 (0.75, 1.41) 1.47 (0.78, 2.77)
Secondary & above 417 (38.3) 0.67 (0.50, 0.91)* 0.88 (0.48, 1.63)
Disclosure of HIV+ status 1089
To spouse/family members only 616 (56.6) 1.00 1.00
To relatives/friends only 86 (7.9) 0.90 (0.55, 1.47) 0.38 (0.12, 1.19)
To spouse/family members & relatives/friends 35 (3.2) 1.14 (0.56, 2.35) 1.47 (0.41, 5.32)
To no one 352 (32.3) 1.33 (1.01, 1.75)* 0.65 (0.37, 1.14)
Place of residence 1089
Gondar 796 (73.1) 1.00 1.00
Out of Gondar 293 (26.9) 0.89 (0.67, 1.18) 1.07 (0.61, 1.87)
History of TB treatment 1044
Yes 222 (21.3) 1.00 1.00
No 822 (78.7) 1.37 (0.99, 1.89) 0.73 (0.39 , 1.35)
CD4 cell count/μl 1076
≤ 200 611(56.8) 1.00 1.00
201-250 111(10.3) 2.48 (1.59, 3.87)* 2.22 (0.95, 5.19)
251-300 75 (7.0) 2.38 (1.41, 4.02)* 2.64 (1.05, 6.65)*
301-350 64 (5.9) 5.75 (3.37, 9.82)* 5.21 (1.94, 13.99)*
> 350 215 (20.0) 10.76 (7.52, 15.38)* 12.10 (6.33, 23.12)*
WHO stage 1070
Stage I 257 (24.0) 2.10 (1.39, 3.15)* 2.81 (1.15, 6.91)*
Stage II 194 (18.1) 1.29 (0.83, 2.01) 1.75 (0.69, 4.45)
Stage III 446 (41.7) 0.82 (0.56, 1.21) 1.72 (0.77, 3.81)
Stage IV 173 (16.2) 1.00 1.00
Next appointment record 1089
Yes 784 (72.0) 1.00 1.00
No 305 (28.0) 173.30 (99.25, 302.61)* 241.39 (119.90, 485.97)*
OR: Odds Ratio, CI: Confidence Interval, * p≤0.05, +A total of 1015 subjects included in the adjusted model.
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examined the socio-demographic and clinical factors asso-
ciated with LTFU during the pre-ART period in Ethiopia
and found that male gender, being unmarried, CD4 cell
count >250 cells/μl, WHO stage I, and not having docu-
mented next appointment date on the medical chart
were all associated significantly with increased odds of
pre-ART LTFU.
Similar with a study conducted in southern Ethiopia
[5], the majority of patients in this study started care
after reaching compromised immune system. This was
shown by the high proportion of patients that had base-
line CD4 count of ≤200 cells/μl and WHO stage III and
IV. In this study males were found to be at higher risk of
LTFU before starting ART. This finding was consistent
with studies conducted in Uganda [17] and Malawi [14].
Unlike the findings of previous studies, this study identi-
fied an association between marital status and pre-ART
LTFU. In this study being married was associated with
lower odds of pre-ART LTFU compared to those who
had never married. This could be explained by the im-
portance of family support in HIV care [18,19].
Low CD4 cell count was identified as an important risk
factor for pre-ART LTFU at a semi-private hospital in
Durban, South Africa [16] and in a non-governmental
clinic in Jinja, Uganda [17]. In studies conducted in
Malawi and Kenya, having an advanced WHO stage of ill-
ness (III and IV) was identified as a risk factor for pre-
ART LTFU [14]. Our study findings contradicted this,
with increased odds of LTFU among patients with bet-
ter immune system indicators (higher CD4 cell count
and less advanced WHO stage), and this could be due
to methodological differences with respect to oper-
ational definitions and also differences between the
study settings. Unlike our study, which defined pre-
ART patients as all newly enrolled HIV patients who
did not start ART, studies conducted in South Africa
[16], Uganda [17], Malawi and Kenya [14] focused on
pre-ART patients with low CD4 cell count and ad-
vanced WHO stage. These groups of patient are not
representative of all pre-ART patients who are enrolled
in HIV chronic care and expected to have periodic
follow-up visits. On the other hand, our finding regard-
ing the association between less advanced disease stage
and pre-ART LTFU was consistent with a study
conducted in southern Ethiopia that employed a similar
operational definition and study settings [5]. Further-
more, we found that the risk of pre-ART LTFU in-
creased progressively with increasing CD4 cell count,
indicating a dose response relationship. This finding
was supported by the study conducted in South Africa
where the probability of returning to care dropped sub-
stantially for patients with higher CD4 cell count [10].
Part of the explanation for the increased odds of pre-ART LTFU among patients with better immune status
or less advanced disease stage could result from pa-
tients’ self-assessment of feeling healthy and, therefore,
not in need of health care [20].
The other contributory factor to pre-ART LTFU iden-
tified in this study was lack of documentation of pa-
tients’ next appointment date by clinicians. Studies
conducted in Malawi and Kenya also identified patients’
charts that did not have the next appointment date spe-
cified, but excluded them from the analysis [14]. We in-
cluded these individuals without recorded appointment
date because lack of documentation itself might be indi-
cative of the type of service patients received about spe-
cific follow-up visit days and could have an effect on
patients’ follow-up. Indeed, this study found that pa-
tients without a record of the next visit date had a high
chance of being LTFU during the pre-ART period. This
could be because a clinician who failed to record the
next appointment date on the patient’s chart might also
omit to provide written or verbal information for the pa-
tient about the specific date of the next visit.
The main limitation of the study was the lack of or
missing data regarding baseline socio-demographic and
clinical variables and also our inability to locate some of
the patient charts during the data collection period.
Charts with no baseline information on the intake form,
especially demographic data, and chart numbers that
could not be found during random sampling were re-
placed by the next study subject (number) in the list of
the study population. The rate of replacement of sam-
ples was low (5.5%). The other limitation was the study
setting that was confined to only one university hospital,
and hence the result might not be extrapolated to other
locations.
Conclusions
Our study found that patients who were less ill were
more likely to be LTFU during the pre-ART period. The
risk of pre-ART LTFU increased progressively with in-
creasing CD4 cell count. These findings highlight the
importance of giving greater attention to the care of pre-
ART patients, starting from the time that they learn of
their HIV positive serostatus. The standard of care for
pre-ART patients needs to be revised to include mea-
sures to encourage follow-up, including early initiation
of ART. Efforts to prevent pre-ART LTFU should be
strengthened through mechanisms that proactively
indentify and manage pre-ART patients who are likely
to be non-adherent to care and become LTFU. There
should be standardized definition of pre-treatment LTFU
and appointment system that can monitor and easily
flag-out missed appointment patients. Intensive adher-
ence counseling and adequate information should be
given to patients at-risk of LTFU at each visit especially
Ahmed et al. BMC Public Health 2013, 13:867 Page 9 of 9
http://www.biomedcentral.com/1471-2458/13/867during the first visit. The completeness of the medical
records, the standard of record keeping and obstacles to
retrieving charts also indicate a serious problem that
needs due attention from clinicians and data personnel.
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